Company profilePharmaceutical#360 of 1,318 in Pakistan✓ No DRAP alerts

SEATLE PHARMA PAKISTAN (PVT) LTD.

Pharmaceutical company · 48 brands · 40 molecules

Ranked #23 of 58 companies in Skin Conditions

48 registered products 39 pharmaceutical brands 40 distinct molecules 0 DRAP alerts

Company overview

48
registered products
39
pharmaceutical brands
40
distinct molecules
8
therapeutic classes
0
DRAP alerts

SEATLE PHARMA PAKISTAN (PVT) LTD. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 48 product registrations across 40 distinct molecules. Its portfolio is concentrated in Skin Conditions and Corticosteroid, Plain. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by SEATLE

21 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

14
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202614

Top molecules by brand count

Ceftriaxone7 brands
Cefixime6 brands
Levofloxacin3 brands
Terbinafine3 brands
Permethrin3 brands
Ivermectin3 brands
Minoxidil2 brands

Therapeutic classes

Skin Conditions · 3Corticosteroid, Plain · 1Antimycotics Systemic Use · 1Ectoparasiticides; Scabicides · 1Anti-Infectives · 1Other Dermatological Preparations · 1Unmapped-Medicine · 1Anti-Acne Preparations · 1

Conditions treated

Hair Loss · 1Fungal Infection · 1Scabies · 1Acne/Topical · 1Infection/Allergy · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official49 products · Rs 79.79 – Rs 762.72
DVAGO2 products · Rs 275.5 – Rs 353
Servaid8 products · Rs 126.27 – Rs 659.81
Median across source: Rs 314.25

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

MASS PHARMA (PRIVATE) LIMITED holds 121 molecules not in this portfolio
000 I.UAcitretinAcitretin UspAmikacinAmlodipineAmlodipine Usp
BIO LABS (PVT) LTD. holds 131 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherArtemetherArtesunate
PEARL PHARMACEUTICALS holds 60 molecules not in this portfolio
AcitretinAcyclovirAmlodipineArtemetherArtemether LumefantrineAscorbic Acid

Get the full profile for SEATLE

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.